Q3 Revenue Drops 21% to $62.3M as Adjusted EBITDA Falls 27%
XPOF sits 24% above its 52-week low of $3.565.
Summary
Revenue fell 21% year over year to $62.3M and Adjusted EBITDA dropped 27% to $24.3M from $33.5M, so profit is shrinking faster than sales. Adjusted net income collapsed to $2.2M from $19.3M, though GAAP net income swung to a $4.9M profit from a $6.7M loss a year ago. The company said the revenue decline was expected, and the board's strategic alternatives review is still running with no outcome announced. Balance sheet is the pressure point: $27.2M of cash against $521.1M of long-term debt. This lands on top of an activist fight — Fund 1 Investments holds roughly 18% economic exposure and has proposed a $5.61-$7.00 per share cash take-private, while the company's 19.9% poison pill blocks it from going higher without board approval. Weak numbers plus a live buyout bid means the strategic review, not the quarter, is what sets the price from here.
At the time of this announcement, XPOF was trading at $4.42 on NYSE in the Trade & Services sector, with a market capitalization of approximately $217.7M. The 52-week trading range was $3.57 to $9.25. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.